Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide
3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize …
3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize …
Cancer cell-erythrocyte hybrid membrane coated gold nanocages for near infrared light-activated photothermal/radio/chemotherapy of breast cancer
M Sun, Y Duan, Y Ma, Q Zhang - International journal of …, 2020 - Taylor & Francis
Background The combination of radiotherapy (RT) and chemotherapy, as a standard
treatment for breast cancer in the clinic, is unsatisfactory due to chemoradioresistance and …
treatment for breast cancer in the clinic, is unsatisfactory due to chemoradioresistance and …
Integrated proteomic, transcriptomic, and genomic analysis identifies fibrinogen beta and fibrinogen gamma as key modulators of breast cancer progression and …
H Patadia, A Priyadarshini… - … Research Journal (BBRJ …, 2022 - journals.lww.com
Background: As per the WHO, more than 2 million new cases are diagnosed with breast
cancer and more than 685,000 deaths have been reported in 2020. Incidence of recurrence …
cancer and more than 685,000 deaths have been reported in 2020. Incidence of recurrence …